PE Tech Report


Like this article?

Sign up to our free newsletter

JP Morgan launches new life sciences private capital team

JP Morgan Asset Management has launched a new life sciences private equity team, Life Sciences Private Capital, which will invest in both early and growth stage healthcare companies across multiple strategies aligned to specific market opportunities. 

The team, led by new hire Dr Stephen Squinto as chief investment officer and managing partner of Life Sciences Private Capital, will focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity, AI/ML platforms, Metabolic Diseases and Neuropsychology.
Squinto joins from OrbiMed Advisors and brings more than 30 years of experience in the biotechnology company building and investing space, having co-founded and built numerous biotechnology companies including Alexion Pharmaceuticals and acting as a key scientific founder of Regeneron Pharmaceuticals. 
Joining Squinto as co-managing partners of the investment strategy are Dr Gaurav Gupta and Anya Schiess. Gupta founded life science investment firm Ascendant BioCapital and was previously involved in private equity investments at OrbiMed Advisors. Schiess has over 25 years of experience in healthcare investing and most recently was Co-Founder and General Partner of Healthy Ventures. 

Like this article? Sign up to our free newsletter